Showing results (221-230 of 830) with videos related to
Sort By:
Pageof 83
Pharmacogenetics|June 1, 1996
A study of the dopamine D2 receptor gene in pathological gamblingD E Comings, R J Rosenthal, H R Lesieur, et al.Pharmacogenetics|June 1, 1996
Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disordersH M Lachman, D F Papolos, T Saito, et al.Pharmacogenetics|February 1, 1996
Isolation and characterization of a new rat P450 (CYP3A18) cDNA encoding P450(6)beta-2 catalyzing testosterone 6 beta- and 16 alpha-hydroxylationsK Nagata, N Murayama, M Miyata, et al.Pharmacogenetics|February 1, 1996
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and genderM J Ratain, R Mick, L Janisch, et al.Pharmacogenetics|October 1, 1991
Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypeR Tyndale, T Aoyama, F Broly, et al.Pharmacogenetics|October 1, 1991
Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidenceN Caporaso, M T Landi, P VineisPharmacogenetics|December 1, 1991
Pharmacogenetics of caffeine and caffeine-halothane contractures in biopsies of human skeletal muscleW Kalow, S Sharer, B BrittPharmacogenetics|April 20, 1999
N-acetyltransferase (NAT2) genotype and susceptibility of sporadic Alzheimer's diseaseL Rocha, C Garcia, A de Mendonça, et al.Pharmacogenetics|April 20, 1999
Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variantsA Cravchik, D R Sibley, P V GejmanPharmacogenetics|April 20, 1999
CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's diseaseA Atkinson, A B Singleton, A Steward, et al.Pageof 83